Evidence for Recombination of Live, Attenuated Immunodeficiency Virus Vaccine with Challenge Virus to a More Virulent Strain
AUTOR(ES)
Gundlach, Björn R.
FONTE
American Society for Microbiology
RESUMO
Live, attenuated immunodeficiency virus vaccines, such as nef deletion mutants, are the most effective vaccines tested in the simian immunodeficiency virus (SIV) macaque model. In two independent studies designed to determine the breadth of protection induced by live, attenuated SIV vaccines, we noticed that three of the vaccinated macaques developed higher set point viral load levels than unvaccinated control monkeys. Two of these vaccinated monkeys developed AIDS, while the control monkeys infected in parallel remained asymptomatic. Concomitant with an increase in viral load, a recombinant of the vaccine virus and the challenge virus could be detected. Therefore, the emergence of more-virulent recombinants of live, attenuated immunodeficiency viruses and less-aggressive wild-type viruses seems to be an additional risk of live, attenuated immunodeficiency virus vaccines.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=111861Documentos Relacionados
- Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge
- Immunization with a Live, Attenuated Simian Immunodeficiency Virus Vaccine Leads to Restriction of Viral Diversity in Rhesus Macaques Not Protected from Pathogenic Challenge
- Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.
- Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains
- Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.
